What do we know about Ocrevus rebound? Is it like Tysabri?
The short answer is ‘no’. While the experience of Ocrevus is still limited, the similar biological Rituximab, which is given off label for MS suggests no significant rebound coming off these b-cell targeting therapies.
A. Scott Nielsen MD MMSc
Neurologist and MS Specialist at Kaiser Permanente